Terri,
Most of the time, I am just fairly good at remembering where I read something.
Just to throw a wrinkle into things, there is some evidence that, for at least some Her2+ ER+ patients, Tamoxifen acts as an agonist, rather than an antagonist. My personal belief is that this is one of the reasons virtually all Her2+ patients score highly on the Oncotype Dx test, which was validated (retrospectively) in a set of patients ER+ node negative treated only with Tamoxifen. (I want to stress that this is my personal opinion only; I haven't seen anything written on it).
As to the PR- phenotype, there are a lot of articles written about it; it tends to be Tamoxifen resistant; if you google "Tamoxifen resistance" you will get a lot of hits on articles that discuss it.
I am providing links to some older threads where a lot of these issues have been discussed:
http://her2support.org/vbulletin/sho...&highlight=PR-
http://her2support.org/vbulletin/sho...&highlight=PR-
http://her2support.org/vbulletin/sho...&highlight=PR-
http://her2support.org/vbulletin/sho...&highlight=PR-
The last link above contains some research I did some months back concerning the prognostic significance of PR+ vs. PR-, ER+ bc. I am ER+ (80%) and PR+ (50%). I am not familiar with Dr. Lee's books.
Hopeful